RNA, U6 small nuclear 1061, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU6-1061P profile across patient tissues and cancer cell-line models. RNU6-1061P expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, RNU6-1061P is differentially expressed in 9, with the highest sampling consensus in LUSC. Additionally, RNU6-1061P RNA expression shows 10,020 significant gene co-expression associations, with the highest sampling consensus in CESC. Together, these results highlight MESO, LUSC, and CESC as cancer lineages where RNU6-1061P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU6-1061P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU6-1061P survival associations across molecular data types. RNU6-1061P RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU6-1061P RNA expression–survival associations across cancer types. High RNU6-1061P expression shows unfavorable associations in HNSC and DLBC, but favorable associations in MESO, ACC, BRCA and STAD. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for RNU6-1061P RNA expression.
This table summarizes RNU6-1061P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for RNU6-1061P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU6-1061P shows lower tumor expression in LUSC, KIRC, BRCA, THCA and KICH and higher tumor expression in CHOL. The LUSC box plot shows higher RNU6-1061P RNA expression in normal versus tumor tissue (log2 FC = −0.438, t-test p < 0.001).
This table shows molecular features associated with RNU6-1061P in patient tissues and cancer cell lines. In patient samples, RNU6-1061P shows the broadest associations at the RNA and protein expression levels, with CESC recurring as the lineage with the largest associated feature set.
